logoTry Persana

Abalone Bio - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Abalone Bio including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Abalone Bio company logo

Unleashing therapeutic biology.

Abalone Bio develops antibody drugs that activate, allowing the turn-on of previously inaccessible biological activities for therapeutic benefits such as anti-cancer or anti-inflammatory actions.

HeadquartersEmeryville, United States
Team size11-50
Founded2017

What is Abalone Bio? - Company Overview & Details

Abalone Bio is Abalone Bio develops antibody drugs that activate, allowing the turn-on of previously inaccessible biological activities for therapeutic benefits such as anti-cancer or anti-inflammatory actions. Founded in 2017, the company is headquartered in Emeryville, United States.

Who Founded Abalone Bio?

Abalone Bio was founded by Richard Yu.

Who are the Key Executives at Abalone Bio? - Leadership Team

Abalone Bio is led by experienced executives in key positions:

Chief Executive Officer (CEO) of Abalone Bio

Richard YuCEO

Chief Technology Officer (CTO) of Abalone Bio

CTO

About Richard Yu - CEO of Abalone Bio

Richard Yu serves as the Chief Executive Officer of Abalone Bio, leading the company's strategic vision and operations. Connect with them on LinkedIn for professional insights.

Abalone Bio Company Details & Key Information

Where is Abalone Bio located?

Abalone Bio is headquartered in Emeryville, United States.

How many employees does Abalone Bio have?

Abalone Bio has 11-50 employees.

When was Abalone Bio founded?

Abalone Bio was founded in 2017.

Abalone Bio Official Website

How much funding has Abalone Bio raised?

Abalone Bio has raised undisclosed amount across 4 funding rounds. The most recent funding was completed on 2022-02-02.

Funding Overview

Abalone Bio has participated in multiple funding rounds indicating ongoing investment in their growth.

N/A
Total Funding Raised
4
Funding Rounds
2022-02-02
Latest Round

Abalone Bio Funding History

Seed
2022-02-02

Who are the key investors in Abalone Bio?

Investor Information Not Available

Detailed information about Abalone Bio investors is not currently available in our database.

What are Abalone Bio's future plans?

Abalone Bio To continue developing next-generation antibody therapeutic solutions with a focus on obesity treatments.

Abalone Bio Strategic Outlook

Strategic Focus
Defined
2
Key Challenges
2
Growth Opportunities

What challenges does Abalone Bio face?

Abalone Bio has identified 2 key challenges that need to be addressed for continued growth and success.

Key Challenges for Abalone Bio

1

Managing the complexity of drug side effects

2

Securing further funding for advanced development

What opportunities does Abalone Bio have?

Abalone Bio has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for Abalone Bio

1

Collaborations with prestigious institutions like UPenn

2

Expanding research in metabolic disorders

Abalone Bio Strategic Position Summary

Key Focus Areas

Abalone Bio is addressing 2 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about Abalone Bio?

Abalone Bio has 2 recent news updates covering key business developments and market activities.

Abalone Bio News Overview

2
Recent Articles
Active
Media Coverage
2025-03-18
Latest Update

What is Abalone Bio in the news for?

Abalone Bio is currently featured in news for Abalone Bio, Inc. partners with University of Pennsylvania. and other significant business developments.

Recent News Articles About Abalone Bio

Article 1
2025-03-18

Abalone Bio, Inc. partners with University of Pennsylvania.

Abalone Bio and the University of Pennsylvania announce a collaboration to develop next-generation antibody-based obesity drugs.

biobuzz.io
Read News
Article 2
2025-03-17

Abalone Bio, Inc. is developing antibody-based obesity drugs.

Abalone Bio collaborates with UPenn to advance new antibody-based obesity treatments targeting functional antibodies.

thepharmaletter.com
Read News

Abalone Bio FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Abalone Bio including information about founders, CEO, funding history, investors, headquarters location, and company details. 14 frequently asked questions covering key information about the company.

Abalone Bio Questions & Answers - Company Information

Q1

What is Abalone Bio?

Abalone Bio develops antibody drugs that activate, allowing the turn-on of previously inaccessible biological activities for therapeutic benefits such as anti-cancer or anti-inflammatory actions.

Q2

Who founded Abalone Bio?

Abalone Bio was founded by Richard Yu.

Q3

Who is the CEO of Abalone Bio?

The CEO of Abalone Bio is Richard Yu. You can find more information about them on their LinkedIn profile.

Q4

Where is Abalone Bio headquartered?

Abalone Bio is headquartered in Emeryville, United States.

Q5

When was Abalone Bio founded?

Abalone Bio was founded in 2017.

Q6

How many employees does Abalone Bio have?

Abalone Bio has 11-50 employees.

Q7

What is Abalone Bio's official website?

You can visit Abalone Bio's official website at https://www.abalonebio.com.

Q8

What was Abalone Bio's latest funding round?

Abalone Bio's latest funding round was a Seed round completed on 2022-02-02.

Q9

Who is founder?

Richard Yu

Q10

What does the company do?

Abalone Bio develops antibody drugs that activate hard-to-drug targets, unlocking therapies with fewer side effects to treat complex diseases.

Q11

Latest funding date?

2022-02-02

Q12

What are the challenges?

Managing the complexity of drug side effects Securing further funding for advanced development

Q13

What are the opportunities?

Collaborations with prestigious institutions like UPenn Expanding research in metabolic disorders

Q14

Latest news?

Abalone Bio and the University of Pennsylvania announce a collaboration to develop next-generation antibody-based obesity drugs. Abalone Bio collaborates with UPenn to advance new antibody-based obesity treatments targeting functional antibodies.

More Information About Abalone Bio

For additional details about Abalone Bio, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.